Ethnobotany, Intellectual Property, and Bioprospecting

Ethnobotany, Intellectual Property, and Bioprospecting are critical concepts at the intersection of traditional knowledge, scientific discovery, and equitable benefit-sharing. This field examines how indigenous communities' deep understanding of plants is utilized for commercial purposes, the legal frameworks governing access to these resources, and the ethical considerations surrounding their exploitation. For students preparing for exams or seeking a comprehensive overview, understanding the history, challenges, and solutions within this area is essential. This article will delve into the core definitions, significant cases, and international protocols that shape this complex landscape.

Ethnobotany, Intellectual Property, and Bioprospecting Explained

Socioethnobotany is the study of compensating indigenous peoples for sharing their ethnobotanical knowledge with the industrialized world. It highlights the ethical and economic dimensions of traditional plant use.

Bioprospecting refers to the collection of plants, animals, microorganisms, and/or indigenous knowledge for discovering genetic or biochemical resources. These resources can be developed into new crops, drugs, or industrial chemicals.

Biopiracy is defined as the illegal or unethical appropriation (often through patents) of indigenous medical or biological knowledge without proper compensation to the original knowledge holders. This practice raises significant concerns about fairness and intellectual property rights.

A Patent grants exclusive rights by a state to an inventor for a fixed period. In exchange, the inventor publicly discloses details of their invention, which must be new, inventive, and industrially applicable (e.g., a device, method, process, or substance).

The Historical Context of Bioprospecting

During the 1980s and early 1990s, the concept of chemical prospecting gained momentum. Rainforests were promoted as a source of potential medicines, linking conservation efforts to economic incentives. The idea was that finding valuable products could help resolve poverty and improve the social status of indigenous peoples.

Major grants were awarded to botanical gardens and universities in the US to collect organisms for screening for potential drug precursors. Notable organizations like the National Cancer Institute (NCI) were involved. A pioneering deal in 1991 saw drug manufacturer Merck strike a $1 million agreement with the Costa Rican government to exploit biodiversity in its national parks.

Indigenous Intellectual Property and Traditional Cultural Expressions

Indigenous Intellectual Property (IP) encompasses the cultural knowledge of indigenous groups, which is often collectively owned and passed down through oral history. This knowledge is deeply embedded in their way of life.

Traditional Cultural Expressions (TCEs) are any forms of artistic and literary expression that embody traditional culture and knowledge. Transmitted from one generation to the next, TCEs include handmade textiles, paintings, stories, legends, ceremonies, music, songs, rhythms, and dance. The World Intellectual Property Organization (WIPO) recognizes these as crucial forms of cultural heritage.

Challenges with Intellectual Property Rights for Indigenous Cultures

Historically, indigenous knowledge, chemical structures, and genes were often viewed as common property, belonging to everybody. This perspective presented significant problems for recognizing and protecting indigenous IP.

Key questions arise: Who owns the IP when communities are permeable and knowledge results from cultural exchange? How can profit generation align with common knowledge and property regimes of indigenous groups? These complexities often led to little incentive to conserve species, habitats, or indigenous cultures.

International Frameworks and Guidelines for Benefit Sharing

Several international agreements and guidelines have emerged to address the ethical and legal complexities of bioprospecting and indigenous intellectual property.

Declaration of Belém (1988)

The First International Congress of Ethnobiology in Belém, Brazil, led to the Declaration of Belém. The International Society of Ethnobiology strongly supports actions such as:

• Developing aid for ethnobiological inventory, conservation, and management.
• Recognizing and consulting indigenous specialists as authorities.
• Guaranteeing human rights, including cultural and linguistic identity.
• Compensating native peoples for the use of their knowledge and biological resources.
• Implementing educational programs to highlight the value of ethnobiological knowledge.
• Including traditional healers and health practices in medical programs.
• Making research results available to native peoples, especially in their native language.
• Promoting information exchange among indigenous peoples on conservation and sustainable resource utilization.

Manila Declaration (1992) on Botanical Collecting Ethics

Adopted at the 7th Asian Symposium on Medicinal Plants and Other Natural Products, the Manila Declaration emphasizes:

• Collaboration & Information Sharing: Working with local scientists, sending reports to host countries, leaving photos for host institutions, depositing duplicates in national museums, and informing collaborators of duplicate locations.
• Compensation: Donating hard-to-procure items to communities, including travel costs for local counterparts in funding applications, and acknowledging collaborators and host institutions.
• Conservation: Collecting only what is necessary, especially for high-value, rare, or endangered plants, and informing host institutions about rare plant locations.

Convention on Biological Diversity (CBD) (1993)

Signed by 140 nations at the Earth Summit in Rio de Janeiro, the CBD has three main objectives:

1. Conservation of biological diversity.
2. Sustainable use of its components.
3. Fair and equitable sharing of benefits arising from the utilization of genetic resources.

Nagoya Protocol (2010)

As a supplementary agreement to the CBD, the Nagoya Protocol focuses on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization. Its three pillars are:

• Access (A): Ensuring access to genetic resources.
• Benefit Sharing (B): Ensuring the fair and equitable sharing of benefits.
• Compliance (C): Establishing measures to ensure compliance with access and benefit-sharing rules.

The Access and Benefit-Sharing Clearing-House (ABSCH) serves as a platform for exchanging information and facilitating the implementation of the Nagoya Protocol.

Guidelines for Research Projects

To ensure ethical bioprospecting, several agreements are crucial:

• Prior Informed Consent (PIC) Agreement: Obtained from the farmer or community by the researcher before any activity or use of traditional knowledge, after full disclosure of research intent and scope.
• Material Transfer Agreement (MTA): Specifies elements related to material identification, purpose of biological sample transference, and provider/user rights and obligations.
• Benefit Sharing Agreement: An adapted MTA that includes provisions on what benefits will be shared between parties and how.
• Information Sharing Agreement: Defines conditions for information exchange and cooperation among project partners and for third beneficiaries' access.

Notable Cases in Ethnobotany and Intellectual Property Rights

These real-world examples illustrate the complexities and impacts of bioprospecting and biopiracy.

The Madagascar Periwinkle Case

• Plant: Catharanthus roseus (L.) G. Don (Apocynaceae), also known as the Madagascar Periwinkle.
• Traditional Uses (Madagascar): Treatment of diabetes, hemostatic, tranquilizer, blood pressure reducer, disinfectant.
• Discovery: The aerial parts contain alkaloids (0.2-1%). Vincristine (3g/t) and vinblastine were isolated.
• Commercialization: Vincristine (Oncovin®) was approved by the FDA in July 1963 and patented/marketed by Eli Lilly and Company. It is used in chemotherapy for non-Hodgkin's lymphoma and acute lymphoblastic leukemia.
• Controversy: The country of origin, Madagascar, did not receive any payment from the substantial revenues generated (e.g., $15.6 billion in 2006 for Eli Lilly). This case is often cited as a prime example of biopiracy.

The Arogyapacha (Jeevani) Case

• Plant: Trichopus zeylanicus Gaertn. (Dioscoreaceae), known as Arogyapacha, grows in Malaysia, Singapore, Sri Lanka, Thailand, and India.
• Traditional Uses: Used for centuries by the Kaani tribal community in Kerala, India, for its anti-fatigue properties.
• Research & Development: Scientists from the Regional Research Laboratory Jammu and the Nehru Tropical Botanic Garden and Research Institute (TBGRI) verified tribal claims and developed an anti-fatigue herbal drug called Jeevani.
• Equitable Benefit Sharing: The agreement between TBGRI and the producing company included provisions for 50% of the license fee and a 2% royalty at ex-factory sales price to be paid to the Kani tribal families. This stands as a successful example of benefit sharing.

Basmati Rice Case

• Product: 'Basmati' (Oryza sativa L., Aromatica Group), a fragrant rice cultivated in India for thousands of years, known for its pandan-like "nutty" flavor (due to 2-acetyl-1-pyrroline).
• Controversy: In 1997, RiceTec Inc. (USA) was granted U.S. Patent No. 5,663,484 on hybrid basmati rice lines and grains, including their Texmati® Rice. This sparked outrage in India, which threatened to take the matter to the World Trade Organization (WTO) as a violation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement.
• Outcome: Due to the international pressure and a re-examination by the US Patent and Trademark Office, RiceTec lost most of the claims of the patent, including the right to call their rice lines "basmati."

Xa21 Gene in Wild Rice Case

• Plant: Oryza longistaminata A. Chev. & Roehr. (Poaceae), a wild red rice native to sub-Saharan Africa.
• Discovery: Found to be resistant against Xanthomonas oryzae pv. oryzae ('Xoo'), the bacterium causing leaf blight in rice.
• Genetic Engineering: A gene, 'Xa21', from a specimen in Mali was used by the University of California at Davis (UC Davis) for the development of genetically engineered resistant rice plants, reducing the need for chemical pesticides.
• Benefit Sharing: UC Davis patented the gene and established a Genetic Resources Recognition Fund to finance Fellowships at UC Davis for students from source countries. Researchers in source countries can access genes and transgenic varieties produced by UC Davis at cost price.

Decline of Bioprospecting and New Solutions

From the late 1990s onward, bioprospecting saw a decline. Macilwain (1998) noted that "When rhetoric hits reality..." the gold rush of prospecting scientists did not materialize as expected.

Reasons for Decline

• Economics: Developing drugs from natural products is an expensive and time-consuming process. Only about 1 in 10,000 samples shows promising biological activity, with an even smaller fraction reaching clinical trials and market. The time from sampling to market can take 8 to 15 years.
• Alternatives: Cheaper possibilities arose, such as combinatorial chemistry, which offered more efficient drug discovery methods.

Traditional Knowledge Databases

To prevent further cases of biopiracy, initiatives like the Traditional Knowledge Digital Library (TKDL) were established.

• TKDL (2001): An Indian digital knowledge repository of traditional knowledge, particularly medicinal plants and formulations used in Indian systems of medicine. It has signed agreements with international patent offices (EPO, UK IPO, USPTO) to prevent inappropriate patenting of traditional knowledge.

Conclusion: Navigating the Future of Ethnobotany and Bioprospecting

The field of Ethnobotany, Intellectual Property, and Bioprospecting remains a dynamic and vital area of study. As developing countries hold the bulk of the world's biological and cultural diversity, while industrial countries possess primary expertise and technology for product development, the basic conflict persists.

Socioethnobotanical principles, such as those taught at institutions like the Czech University of Life Sciences Prague, are crucial for navigating these ethical, legal, and political issues. Ensuring fair access and equitable benefit-sharing through protocols like the Nagoya Protocol and transparent agreements is paramount for sustainable development and respecting indigenous rights.

Frequently Asked Questions (FAQ)

What is the main difference between bioprospecting and biopiracy?

Bioprospecting is the ethical and legal exploration of biological resources and traditional knowledge for commercial or scientific use, with proper agreements for access and benefit-sharing. Biopiracy, on the other hand, is the illegal or unethical appropriation of these resources and knowledge, often without consent or fair compensation.

Why is indigenous intellectual property so important in ethnobotany?

Indigenous intellectual property is crucial because it represents generations of accumulated knowledge about local biodiversity, including medicinal uses, agricultural practices, and sustainable resource management. Recognizing and protecting it ensures cultural preservation, promotes ethical research, and allows for equitable benefit-sharing when this knowledge contributes to commercial products.

What are the key international agreements that govern access and benefit-sharing?

The primary international agreements are the Convention on Biological Diversity (CBD), which established the framework for conservation, sustainable use, and equitable benefit-sharing, and its supplementary agreement, the Nagoya Protocol, which provides a transparent legal framework for access to genetic resources and the fair and equitable sharing of benefits arising from their utilization. The Declaration of Belém and Manila Declaration also provide important ethical guidelines.

How does the Madagascar Periwinkle case illustrate the problems with biopiracy?

The Madagascar Periwinkle case highlights biopiracy because a plant with traditional medicinal uses in Madagascar led to the development of life-saving cancer drugs (vincristine and vinblastine) that generated billions in revenue for a pharmaceutical company. However, Madagascar, the country of origin and source of the traditional knowledge, received no direct financial benefit or compensation, demonstrating a severe lack of equitable benefit-sharing.